MANNKIND CORP Operating Lease Liability
MANNKIND CORP (MNKD) had Operating Lease Liability of $11.76 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability $11.76M.
- 2026-03-31: Operating Lease, Liability $12.24M.
- 2025-12-31: Operating Lease, Liability $12.80M.
- 2025-09-30: Operating Lease, Liability $12.21M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $11.76M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $12.24M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $12.80M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $12.21M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $12.72M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $13.51M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $14.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $5.04M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $5.26M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $5.35M 10-K · filed 2025-02-26 |
| 2023-09-30 | $5.47M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.59M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $5.73M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $6.65M 10-K · filed 2024-02-27 |
| 2021-12-31 | $2.42M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |